Amgen Recalls Products for Glass Flakes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Amgen Recalls Products for Glass Flakes


ePT--the Electronic Newsletter of Pharmaceutical Technology

Amgen (Thousand Oaks, CA) issued a voluntary recall last week of certain lots of Epogen and Procrit (epoetin alfa) vials. The injectable products, used to treat anemia related to HIV therapy, chronic renal failure, and chemotherapy, may contain “extremely thin glass flakes (lamellae) that are barely visible,” says the press release. The lamellae, says the release, resulted from the interaction of the formulation with glass vials over the shelf life of the product. Approximately 200 lots of Epogen are being recalled, and 155 of Procrit are being recalled. Potential financial implications have not been released.

The company, along with Centocor Ortho Biotech Products, the authorized distributor of Procrit in the United States, found that the glass flakes have low potential for affecting patients. Although there have been no adverse event reports or complaints [as of Sept. 24, 2010], “potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic, and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity,” according to the Amgen release.

The recall is being conducted in cooperation with the US Food and Drug Administration. Of note, Amgen is the manufacturer of both Epoetin alfa products, which are manufactured in Puerto Rico, but Johnson & Johnson licenses and markets the product under the Procrit brand.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here